Dec 16, 2024 · Some side effects of tirzepatide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the …

The most common tirzepatide side effects include abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, gastroesophageal reflux disease, hair loss, hypersensitivity reactions, injection site reactions, nausea, and vomiting, which affects 5% or more patients.

Dec 18, 2023 · The most common tirzepatide side effects are usually temporary and include nausea, diarrhea, and stomach pain. A decreased appetite, burping, and flatulence (gas) are also typical.

Dec 30, 2024 · Learn about the side effects of Mounjaro (tirzepatide), from common to rare, for consumers and healthcare professionals.

Jul 24, 2024 · What are the serious side effects of Mounjaro? While less common, the most serious side effects of Mounjaro are described below, along with what to do if they happen. Severe Allergic...

Jan 12, 2024 · Zepbound (tirzepatide) is a prescription drug that’s used for weight loss in certain people. Zepbound can cause side effects that range from mild to serious. Examples include nausea, diarrhea,...

Nov 21, 2024 · Common side effects of tirzepatide include nausea, diarrhea, or constipation. Side effects subside as your body adjusts the medication. Following the recommended dosing …

Jan 13, 2025 · Serious side effects of Tirzepatide include: Rare side effects of Tirzepatide include: Seek medical care or call 911 at once if you have the following serious side effects: Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

Oct 22, 2024 · Serious side effects that have been reported include: Severe digestive problems, which may lead to acute kidney injury.* Gallbladder problems.* Pancreatitis.* Risk of thyroid...

Rates of fatal AEs, severe hypoglycemia, acute pancreatitis, cholelithiasis, and cholecystitis were extremely low (≤ 1%) across all doses of tirzepatide. Tirzepatide is associated with a dose-dependent increase in incidence of GI AEs and AEs leading to drug discontinuation.